100007-53-2

Basic information

• Product Name: α-Etoposide
• Synonyms: Etoposide Impurity C;alpha-Etoposide;(5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-alpha-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one;(5S,5aR,8aR,9R)-5-[(7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
• CAS NO: 100007-53-2
• Molecular Formula: C₂₉H₃₂O₁₃
• Molecular Weight: 588.56
• Product Categories: Carbohydrates & Derivatives, Chiral Reagents, Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 100007-53-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 798.1±60.0 °C(Predicted)
• Appearance: /
• Density: 1.55±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.94±0.40(Predicted)
• CAS DataBase Reference: α-Etoposide(CAS DataBase Reference)
• NIST Chemistry Reference: α-Etoposide(100007-53-2)
• EPA Substance Registry System: α-Etoposide(100007-53-2)

Safety Data

• Hazardous Substances Data: 100007-53-2(Hazardous Substances Data)

Usage

Description

α-Etoposide, also known as VP-16, is a potent cytotoxic agent and an antineoplastic drug that belongs to the class of topoisomerase inhibitors. It functions by inhibiting the activity of topoisomerase II, an enzyme essential for DNA replication, thus disrupting the process and leading to the prevention of cancer cell proliferation.

Uses

Used in Anticancer Applications:
α-Etoposide is used as an anticancer agent for the treatment of various malignancies, including testicular, ovarian, small-cell lung, and lymphoid cancers. It exerts its effects by targeting topoisomerase II, which is crucial for DNA replication, ultimately leading to the prevention of cancer cell growth and proliferation.
Used in Drug Delivery Systems:
In the pharmaceutical industry, α-Etoposide is utilized in the development of drug delivery systems to enhance its bioavailability, targeting, and therapeutic efficacy. These systems may include liposomes, nanoparticles, or other advanced formulations designed to improve the drug's pharmacokinetics and reduce potential side effects, thereby optimizing its anticancer properties.

Upstream product

• 163959-36-2 etoposide 
• 149312-27-6 4,6-O-ethylidene-1,2,3-tri-O-(dichloroacetyl)-α-D-glucopyranose 
• 149312-24-3 1-O-(trimethylsilyl)-4,6-O-ethylidene-2,3-di-O-(dichloroacetyl)-β-D-glucopyranose 
• 18465-50-4 4,6-O-ethylidene-D-glucopyranose 

Relevant articles and documents

Preparation method of etoposide, teniposide and analogs of etoposide and teniposide

The invention discloses a preparation method of etoposide, teniposide and analogs of etoposide and teniposide. The preparation method includes the following steps of 1, selective protection of 4'domethylpodophyllotoxin4'hydroxy; 2, introduction of 4 hydroxy hydroxyl; 3, removal of a protecting group. The method is mild in reaction condition and environmentally friendly, and the yield and purity of the products are high.

Epimerization and racemization of some chiral drugs in the presence of human serum albumin

-